

### **Amendments to the Specification**

Please delete the title on page 1 and page 61 of the specification, and replace it with the following:

-- Novel Antiangiogenic Peptide Agents ~~and Their Therapeutic and Diagnostic Use~~ --

Please amend the paragraph beginning on page 1, paragraph [001] as follows:

--[001] This application is a continuation application of U.S. Application Serial No. 09/819,094, filed March 27, 2001, now abandoned, which is a continuation of U.S. Application Serial No. 09/076,675, filed May 12, 1998, now abandoned, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60/046,394, now abandoned, all of which are incorporated herein in their entirety. --

### **Amendments to the Abstract**

Please replace the current abstract found on page 61, with the paragraph below wherein deletions in the original text are shown in strike-out and additions are shown in underlining. A separate sheet containing the new Abstract is also enclosed.

#### **--Abstract of the Disclosure**

The current invention provides ~~concerns~~ novel antiangiogenic peptides which correspond to about 133 ~~10 to about 150~~ consecutive amino acids of the N-terminal sequence ~~sequences~~ of human growth hormone, human placental lactogen, human growth variant hGH-V, and prolactin, ~~and their use in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy involving abnormalities of placental vascularization.~~